RTP Mobile Logo
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Hepatobiliary Cancers (Webinar Video Proceedings)
Released June 2022

Featuring perspectives from Dr Richard Finn and Ms Amanda Wagner. Published June 6, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with hepatobiliary cancers.

    LEARNING OBJECTIVES

    • Consider the impact of age, performance status and other clinical factors on the selection of up-front therapy for unresectable or metastatic hepatocellular carcinoma (HCC), and counsel patients regarding personalized treatment recommendations.
    • Appreciate Phase III data with novel first-line combination strategies for unresectable or metastatic HCC, and discuss how these regimens may be optimally integrated into patient care.
    • Communicate the benefits and risks of approved systemic interventions to patients with progressive HCC to facilitate shared decision-making.
    • Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biologic rationale for efforts to exploit documented abnormalities in patients.
    • Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
    • Develop an understanding of available clinical trial findings with isocitrate dehydrogenase 1 (IDH1) inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation, and identify individuals for whom this novel strategy is warranted.
    • Evaluate available data documenting the efficacy of anti-PD-1/PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers, and consider the potential role of this strategy.
    • Understand the side effects and toxicities associated with various agents and regimens commonly used in the management of advanced HCC and other cancers of the biliary tract, and implement early and effective responses to improve patient quality of life and maintain treatment.
    • Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC and other biliary tract cancers, and appropriately refer patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 1.25 contact hours is provided by RTP during the period of June 2022 through June 2023.

    This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2022/Hepatobiliary/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2022Hepatobiliary/NCPD.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Richard S Finn, MD
    Professor, Department of Medicine, Division of Hematology/Oncology
    David Geffen School of Medicine at UCLA
    Director, Signal Transduction and Therapeutics Program
    Jonsson Comprehensive Cancer Center at UCLA
    Los Angeles, California

    Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: Adaptimmune, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CStone Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Contracted Research (to UCLA): Adaptimmune, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc.

    Amanda K Wagner, APRN-CNP, AOCNP
    GI Malignancies
    The James Cancer Hospital
    The Ohio State University
    Columbus, Ohio

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, and Merck.

    Release date: June 2022
    Expiration date: June 2023

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):